{"id":796,"date":"2013-07-01T14:10:36","date_gmt":"2013-07-01T14:10:36","guid":{"rendered":"http:\/\/stg-blogs.bmj.com\/spcare\/?p=796"},"modified":"2013-07-01T14:12:49","modified_gmt":"2013-07-01T14:12:49","slug":"news-and-updates-from-www-palliativedrugs-com-48","status":"publish","type":"post","link":"https:\/\/stg-blogs.bmj.com\/spcare\/2013\/07\/01\/news-and-updates-from-www-palliativedrugs-com-48\/","title":{"rendered":"News and updates from www.palliativedrugs.com"},"content":{"rendered":"<p><b><i>Selected items from the News and Latest Additions sections of\u00a0<a href=\"http:\/\/www.palliativedrugs.com\/\">www.palliativedrugs.com<\/a>, the world\u2019s leading palliative care website.<\/i><\/b><\/p>\n<p><b><br \/>\nSafety updates<\/b><\/p>\n<p><b>Thalidomide: increased risk of haematological second primary malignancies<\/b><\/p>\n<p>The MHRA has highlighted the risk of haematological second primary malignancies (acute myeloid leukaemia and myelodysplastic syndromes) when treating patients with thalidomide. The data was from an ongoing study of patients with newly diagnosed multiple myeloma who were receiving melphalan, prednisolone and thalidomide compared with lenalidomide plus dexamethasone. For more information click <a href=\"http:\/\/www.mhra.gov.uk\/Safetyinformation\/DrugSafetyUpdate\/CON282739\"><span style=\"text-decoration: underline\">here<\/span><\/a>.<\/p>\n<p><b><br \/>\nDrug updates<br \/>\n<\/b><\/p>\n<p><b>Cyclizine 50mg\/mL injection supply problem resolved<\/b><\/p>\n<p>Cyclizine injection 50mg\/mL (Valoid; Amdipharm) is now available through the usual wholesalers in unrestricted quantities.<\/p>\n<p><b><br \/>\nLatest additions<\/b><\/p>\n<p><b>PCF updated monographs<\/b><\/p>\n<p>The online <a href=\"http:\/\/www.palliativedrugs.com\/index.html\"><span style=\"text-decoration: underline\">Palliative Care Formulary (PCF)<\/span><\/a>\u00a0is being continually updated. The following monographs have been updated during May 2013 and supersede those in the publication of the 4<sup>th<\/sup> edition of the Palliative Care formulary (PCF4). They can be accessed from the formulary section of the website:<\/p>\n<p>Chapter 2: <a href=\"http:\/\/www.palliativedrugs.com\/formulary\/en\/anticoagulants.html\">Anticoagulants<\/a> (new monograph)<\/p>\n<p>Chapter 2: Low Molecular Weight Heparin <a href=\"http:\/\/www.palliativedrugs.com\/formulary\/en\/low-molecular-weight-heparin-lmwh.html\">LMWH<\/a> (also replaces the separate dalteparin and enoxaparin monographs, which are no longer available)<\/p>\n<p>Chapter 5: <a href=\"http:\/\/www.palliativedrugs.com\/formulary\/en\/paracetamol.html\">Paracetamol<\/a><\/p>\n<p>Chapter 27: <a href=\"http:\/\/www.palliativedrugs.com\/formulary\/en\/anaphylaxis.html\">Anaphylaxis<\/a><\/p>\n<p>The first of a new series of Quick Clinical Guides, Quick Clinical Guide: <a href=\"http:\/\/www.palliativedrugs.com\/formulary\/en\/heparin-induced-thrombocytopenia.html\"><span style=\"text-decoration: underline\">Heparin Induced Thrombocytopenia (HIT)<\/span><\/a>\u00a0has been added to the formulary section of the website and can be accessed from the Quick Practice Guide section on the left hand menu or via the new LMWH monograph.<\/p>\n<p>For a full list of all the monographs updated since the publication of PCF4, click <a href=\"http:\/\/www.palliativedrugs.com\/download\/PCF_updated_monographs_list_1305.pdf\"><span style=\"text-decoration: underline\">here<\/span><\/a>.<\/p>\n<p><em>Prepared by Sarah Charlesworth and Andrew Wilcock<\/em><!--TrendMD v2.4.8--><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Selected items from the News and Latest Additions sections of\u00a0www.palliativedrugs.com, the world\u2019s leading palliative care website. Safety updates Thalidomide: increased risk of haematological second primary malignancies The MHRA has highlighted the risk of haematological second primary malignancies (acute myeloid leukaemia and myelodysplastic syndromes) when treating patients with thalidomide. The data was from an ongoing study [&#8230;]<\/p>\n<p><a class=\"btn btn-secondary understrap-read-more-link\" href=\"https:\/\/stg-blogs.bmj.com\/spcare\/2013\/07\/01\/news-and-updates-from-www-palliativedrugs-com-48\/\">Read More&#8230;<\/a><\/p>\n","protected":false},"author":191,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[2833],"tags":[],"class_list":["post-796","post","type-post","status-publish","format-standard","hentry","category-updates-from-www-palliativedrugs-com"],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/stg-blogs.bmj.com\/spcare\/wp-json\/wp\/v2\/posts\/796","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stg-blogs.bmj.com\/spcare\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stg-blogs.bmj.com\/spcare\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/spcare\/wp-json\/wp\/v2\/users\/191"}],"replies":[{"embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/spcare\/wp-json\/wp\/v2\/comments?post=796"}],"version-history":[{"count":0,"href":"https:\/\/stg-blogs.bmj.com\/spcare\/wp-json\/wp\/v2\/posts\/796\/revisions"}],"wp:attachment":[{"href":"https:\/\/stg-blogs.bmj.com\/spcare\/wp-json\/wp\/v2\/media?parent=796"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/spcare\/wp-json\/wp\/v2\/categories?post=796"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/spcare\/wp-json\/wp\/v2\/tags?post=796"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}